Uroplasty announced that ConnectiCare of the Emblem Health family of insurers began coverage of percutaneous tibial nerve stimulation, or PTNS, using its Urgent PC neuromodulation system for the treatment of the symptoms of overactive bladder syndrome. Effective immediately, approximately 240,000 ConnectiCare members in Connecticut and western Massachusetts have access to the PTNS procedure. In addition, the company announced that the California Technology Assessment Forum has concluded that PTNS meets all five of its technology criteria for the treatment of OAB for short term benefit. CTAF is one of the preeminent independent medical technology assessment organizations in the country and its reviews are utilized by many payers and providers to evaluate new medical technology, Uroplasty said.
- Technology & Electronics